Hypofractionated radiotherapy with a tumor bed boost for early breast cancer
Hybrid Techniques Combining Hypofractionated Whole Breast Radiotherapy With Concomitant Tumor Bed Boost in Patients With Breast Cancer
This study is testing a new type of radiation treatment for women with early breast cancer to see if it can better control the disease while shortening the time they need treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 315 (estimated) |
| Ages | 20 Years to 85 Years |
| Sex | Female |
| Sponsor | National Taiwan University Hospital Academic / other |
| Locations | 2 sites (Taipei, Taiwan and 1 other locations) |
| Trial ID | NCT06984250 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of hypofractionated radiotherapy combined with a concomitant tumor bed boost for patients with early-stage breast cancer or ductal carcinoma in situ following partial mastectomy. The approach aims to improve local control of the disease while minimizing treatment duration. Female patients aged 20 and older with a Karnofsky Performance Status of 70% or higher are eligible for participation. The study is observational and focuses on assessing the effectiveness of this treatment regimen.
Who should consider this trial
Good fit: Ideal candidates for this study are female patients with early-stage breast cancer or ductal carcinoma in situ who have undergone breast-conserving surgery.
Not a fit: Patients who are pregnant or require re-irradiation of the thoracic region may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could enhance the effectiveness of radiotherapy for early breast cancer, potentially leading to better patient outcomes.
How similar studies have performed: Other studies have shown promise with hypofractionated radiotherapy approaches, suggesting potential for success in this treatment strategy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female patients with histologically confirmed early-stage breast cancer (T1-2 and N0-1) or ductal carcinoma in situ (DCIS). * Patients undergoing breast-conserving surgery * Age ≥ 20 years * Karnofsky Performance Status (KPS) ≥70% * Life expectancy ≥ 5 years * Adequate renal and hepatic function Exclusion Criteria: * Pregnant patients * Patients requiring re-irradiation of the thoracic region
Where this trial is running
Taipei, Taiwan and 1 other locations
- National Taiwan University Hospital — Taipei, Taiwan, Taiwan (Not_yet_recruiting)
- National Taiwan University Hospital Yunlin Branch — Taipei, Taiwan (Recruiting)
Study contacts
- Study coordinator: Yen-Ting Liu
- Email: nickliucool@ntuh.gov.tw
- Phone: 88697255451
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.